Simple Amino Acid Cocktail Supercharges mRNA and CRISPR Delivery Up to Twenty-Fold

A Metabolic Fix for Genetic Medicine's Biggest Bottleneck

Researchers at Biohub have uncovered a remarkably simple solution to one of the most persistent problems in genetic medicine. By co-injecting three common amino acids alongside lipid nanoparticles, the same delivery technology behind COVID-19 mRNA vaccines, the team achieved up to a twenty-fold increase in mRNA delivery and pushed CRISPR gene editing efficiency from roughly twenty-five percent to nearly ninety percent in a single dose.

The Problem Was Never the Nanoparticle

Rather than trying to build a better nanoparticle, the team led by Daniel Zongjie Wang and Shana O. Kelley investigated why cells inside the body absorb lipid nanoparticles so much less efficiently than cells grown in laboratory dishes. They discovered that when cells were cultured in conditions mimicking the nutrient-lean environment of human blood plasma, nanoparticle uptake dropped by fifty to eighty percent. Metabolic analysis traced the issue to suppressed amino acid pathways, revealing that the cell's own metabolic state was a critical and previously overlooked factor.

A Cocktail of Three Amino Acids

Through systematic screening, the researchers identified an optimised supplement of methionine, arginine, and serine that restored and amplified the cellular uptake pathway. The cocktail worked across intramuscular, intratracheal, and intravenous delivery routes and proved effective regardless of the specific lipid formulation or mRNA cargo used.

Striking Preclinical Results

In mice with drug-induced acute liver failure, lipid nanoparticles carrying growth hormone mRNA produced only a thirty-three percent survival rate when administered alone. With the amino acid supplement, every mouse survived, therapeutic protein levels rose nearly nine-fold, and markers of liver damage dropped to near-healthy levels. In lung-targeted CRISPR experiments, a single dose with the supplement achieved editing efficiencies of eighty-five to ninety percent, a result that could prove transformative for diseases like cystic fibrosis.

A Simple Path Forward

The supplement consists of pharmaceutical-grade amino acids already manufactured at industrial scale and widely considered safe. Unlike approaches requiring redesigned nanoparticles or genetic modification of target cells, the cocktail could simply be mixed into existing injection buffers, making it potentially compatible with any lipid nanoparticle formulation currently in development.